

1 **Original article**

2

3 **Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus**  
4 **dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast**  
5 **cancer: A prospective pilot study**

6

7 **Authors:** Yu Zhang<sup>1,2,3,4†</sup>, Shuo Cao<sup>1†</sup>, Nan Niu<sup>1,2,3†</sup>, Huilian Shan<sup>1†</sup>, Jinqi Xue<sup>1,2,3†</sup>,  
8 Guanglei Chen<sup>1,2,3</sup>, Yongqing Xu<sup>1</sup>, Jianqiao Yin<sup>1</sup>, Chao Liu<sup>1,2,3</sup>, Lisha Sun<sup>1,2,3</sup>, Xiaofan  
9 Jiang<sup>1,2,3</sup>, Meiyue Tang<sup>1</sup>, Qianshi Xu<sup>1,2</sup>, Mingxuan Jia<sup>1</sup>, Xu Zhang<sup>1</sup>, Zhenyong Zhang<sup>1</sup>,  
10 Qingfu Zhang<sup>5</sup>, Jianfei Wang<sup>6</sup>, Ailin Li<sup>1</sup>, Yongliang Yang<sup>7\*</sup>, Caigang Liu<sup>1,2,3\*</sup>

11

12 **Author Affiliations:**

13 <sup>1</sup> Department of Oncology, Shengjing Hospital of China Medical University,  
14 Shenyang, China;

15 <sup>2</sup> Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of  
16 China Medical University, Shenyang, China;

17 <sup>3</sup> Innovative Cancer Drug Research and Development Engineering Center of Liaoning  
18 Province, Shenyang, China.;

19 <sup>4</sup> Department of Gastrointestinal Surgery, Yantai Affiliated Hospital of Binzhou  
20 Medical University, Yantai, China;

21 <sup>5</sup> Department of Pathology, the First Affiliated Hospital and College of Basic Medical  
22 Sciences of China Medical University, Shenyang, China;

23 <sup>6</sup> Jiangsu Hengrui Pharmaceuticals, Shanghai, China;

24 <sup>7</sup> School of Bioengineering, Dalian University of Technology, Dalian, China.

## 25 **Authors' contributions**

26 S. Cao, Data curation, formal analysis, methodology, writing—original draft. G. Chen,  
 27 Data curation, methodology. J. Xue, Data curation, methodology. N. Niu, Validation,  
 28 data curation, formal analysis, methodology, writing—review and editing. Y. Zhang:  
 29 Data curation, formal analysis, methodology. Y. Xu, Methodology. J. Yin,  
 30 Methodology. C. Liu, Formal analysis, methodology. L. Sun, Methodology. X. Jiang,  
 31 Writing-original draft. M. Tang, Data curation. Q. Xu, Formal analysis. M. Jia,  
 32 Methodology. X. Zhang, Methodology. Z. Zhang, Methodology. Q. Zhang, Formal  
 33 analysis. H. Li, Formal analysis. A. Li, Conceptualization, methodology. Y. Yang,  
 34 Methodology, writing—review and editing. Caigang Liu, Conceptualization,  
 35 supervision, project administration, writing—review and editing.

36 Shuo Cao, Yu Zhang, Jinqi Xue and Guanglei Chen contributed equally to this work.

37

## 38 **Corresponding author:**

39 Caigang Liu, MD, PhD

40 Department of Oncology, Shengjing Hospital of China Medical University, Shenyang 110004,

41 China

42 Tel.: 86-18940254967

43 E-mail: liucg@sj-hospital.org

44

45

46

47

48

## 49 **Abstract**

50 **Background:** Both neoadjuvant chemotherapy and endocrine therapy only result in  
 51 trivial pathological complete response rates and moderate objective response rates  
 52 (ORR) in hormone receptor (HR)-positive, human epidermal growth factor receptor-2  
 53 (HER2)-negative breast cancer, more promising alternatives are urgently needed.  
 54 With proven synergistic effect of cyclin dependent kinase 4/6 (CDK4/6) inhibitor and  
 55 radiotherapy in preclinical studies, this pilot study aimed to explore the efficacy and  
 56 safety of neoadjuvant stereotactic body radiation therapy (SBRT) followed by  
 57 dalpiciclib and exemestane in HR-positive, HER2-negative breast cancer.

58 **Methods:** This was a single-arm, non-controlled prospective pilot study. Treatment-  
 59 naïve patients with unilateral HR-positive, HER2-negative breast cancer received  
 60 neoadjuvant radiotherapy (24Gy/3F) followed by dalpiciclib and exemestane for 6  
 61 cycles. The primary endpoint was the proportion of patients with residual cancer  
 62 burden (RCB) score of 0-I. Key secondary endpoints included ORR, biomarker  
 63 analysis, and safety.

64 **Results:** All 12 enrolled patients completed the study treatment and surgery. Two  
 65 (16.7%) of them achieved the RCB 0-I with the ORR of 91.7% (11/12). Analyses of  
 66 tumor specimens showed significant increase of infiltrating T cells rather than

alteration of PD-L1 positive immune cells. The most common grade 3 adverse events (AEs) were neutropenia (66.7%) and leukopenia (25.0%), but no grade 4-5 AE or death occurred.

**Conclusions:** Our results suggested neoadjuvant SBRT followed by dalpiciclib and exemestane are effective and tolerable, and provides novel insights for the neoadjuvant treatment of HR+/HER2- breast cancer, which may be considered as an alternative to patients with HR-positive, HER2-negative breast cancer.

**Funding:** None

**Clinical trial number:** NCT05132790

**Impact statement:** Neoadjuvant SBRT with dalpiciclib and exemestane resulted in a 16.7% RCB 0-I rate and a 91.7% ORR, with acceptable toxicities in HR-positive, HER2-negative breast cancer patients.

## Introduction

Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer is the most prevalent subtype of breast cancer, which accounts for approximately 70% of all breast cancer (Parker et al., 2009). Neoadjuvant chemotherapy (NCT) is recommended as the first-choice for patients with HR-positive, HER2-negative breast cancer, who are candidates for preoperative therapy, according to National Comprehensive Cancer Network (NCCN) guidelines (Gradishar et al., 2022). Neoadjuvant endocrine therapy (NET) is an acceptable, less toxic alternative of NCT. However, less than 10% of patients with HR-positive, HER2-negative breast cancer can achieve pathological complete response (pCR), and only 60% of patients respond to NCT or NET (Sella et al., 2021). Hence, more promising alternatives are urgently needed.

Cyclin dependent kinase 4/6 (CDK4/6) inhibitors are breakthroughs in the treatment of HR-positive, HER2-negative breast cancer, and have a remarkable efficacy in the advanced setting when combined with endocrine therapy (ET) (Finn et al., 2015; Goetz et al., 2017; Hortobagyi et al., 2016). Presently, abemaciclib has been approved for high-risk, early HR-positive breast cancer plus ET as adjuvant treatment and its application is being explored in neoadjuvant setting (neoMONARCH and NCT04293393). However, therapies with combination of CDK4/6 inhibitors and NET only achieve a pCR rate of less than 5% (Hurvitz et al., 2020; Johnston et al., 2019). In the PALLET study, objective response rate (ORR) was not statistically

significantly different between the combinational therapy and monotherapy (54.3% vs 49.5%,  $P = 0.20$ ) (Johnston et al., 2019). Likewise, in the FELINE study, there was no statistical difference in clinical, mammographic, ultrasound or magnetic resonance imaging (MRI) response between letrozole alone and combination of letrozole with a CDK4/6 inhibitor (Khan et al., 2020). Thus, it is reasonable to explore a novel neoadjuvant therapy for HR-positive, HER2-negative breast cancer.

Radiotherapy is one of the most important local methods to control malignancy by breaking DNA in tumor cells (Cox & Swanson, 2013). Stereotactic body radiation therapy (SBRT) is a novel and relatively safe radiotherapy technique and delivers high doses of radiation in a small number of fractions to the tumor lesion while minimizing radiation exposure to the surrounding tissues (Chmura et al., 2021). Currently, neoadjuvant radiotherapy can be applicable for inoperable breast cancer to allow an effective and sometimes more conservative surgery (Cardoso et al., 2018). Preclinical studies have indicated that CDK4/6 inhibitors can sensitize breast cancer cells to radiotherapy, possibly by inhibition of DNA damage repair response, enhancement of apoptosis and blockage of cell cycle progression, and inhibition of intra-tumor cellular metabolism and angiogenesis (Han et al., 2013; A. M. Pesch et al., 2020; G. Petroni et al., 2021). A preclinical study has explored different schedules of combination of radiotherapy and CDK4/6 inhibitors in human and mouse model and demonstrated that radiotherapy followed by CDK4/6 inhibitors can enhance antineoplastic effects, compared with their monotherapy alone or CDK4/6 inhibitors

concurrent with or followed by radiotherapy (G. Petroni et al., 2021) . Moreover, the combination of CDK4/6 inhibitors and radiotherapy can lead to a satisfying overall disease control and safety based on several retrospective studies in metastatic breast cancer (Bosacki et al., 2021) . Nevertheless, the efficacy and safety of this regimen in neoadjuvant treatment of early-stage HR-positive, HER2-negative breast cancer are unknown.

We have conducted a prospective pilot study to determine the efficacy and safety of neoadjuvant radiotherapy followed by dalpiciclib and exemestane in patients with newly-diagnosed early or locally advanced HR-positive, HER2-negative breast cancer. Dalpiciclib (SHR6390) is a potent selective inhibitor of CDK4/6 and exerts synergistic anti-tumor effect when combined with endocrine therapy for advanced luminal breast cancer in the DAWNA-1 trials (Xu et al., 2021) .

## **Methods**

### **Study design**

This single-arm, non-controlled prospective pilot study in women with HR-positive, HER2-negative early or locally advanced breast cancer was registered with ClinicalTrials.gov (NCT05132790).

The study was approved by the Institutional Review Board and Ethics Committee of Shengjing Hospital of China Medical University, according to the Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent was

obtained from each patient.

## Participants

Eligible patients included pre- and post-menopausal women aged between 18 and 75 years, with histologically confirmed HR-positive, HER2-negative (0 or 1+ by immunohistochemistry [IHC], or 2+ by IHC with negative results of fluorescence in situ hybridization) invasive breast cancer at stage II-III with the lesion of  $\geq 2$  cm by MRI. Other main inclusion criteria were Eastern Cooperative Oncology Group performance status 0-1, adequate marrow, hepatic and renal function. The key exclusion criteria included stage IV tumors, inflammatory breast cancer, prior systemic treatment of the current cancer, other malignancies, cardiac disease or history of cardiac dysfunction, pregnancy, lactation, and refusal to use contraception.

## Procedures

SBRT was performed every other day in breast target lesion with a total radiation dose of 24Gy separated by 3 fractions. Within 2-4 weeks after the completion of radiotherapy, individual patients received 6 cycles of combination of oral 150 mg Dalpiciclib daily on days 1-21 of each 4-week cycle and 25 mg exemestane with a total duration of 24 weeks. Patients without menopause were also injected subcutaneously with 3.6 mg goserelin every 4 weeks. All patients received study treatment until completion of all prescribed protocol therapy, disease progression,

unacceptable toxicity, or withdrawal of consent. If disease progression, the patient was either proceed to surgery or received alternative neoadjuvant therapy. Surgery was performed 3-5 weeks after the last dose of dalpiciclib to allow adverse event (AE) recovery. Recommended surgery and adjuvant therapy followed per local guidelines or institutional standards. The necessity of additional chemotherapy for patients with pCR was judged by investigators.

## **Outcomes**

The primary endpoint was the rate of residual cancer burden (RCB) 0-I. Secondary endpoints included ORR (defined as the proportion of patients with complete or partial response according to the Response Evaluation Criteria In Solid Tumors [RECIST] version 1.1 by MRI), pCR rate in the breast and axillary lymph nodes (tpCR; ypT0/is ypN0) and in the breast (bpCR; ypT0/is ypNx), preoperative endocrine prognostic index (PEPI) score for breast cancer-specific survival (BCSS) (PEPI 0), and safety, according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

## **Patient-Reported Outcome (PRO) assessments**

In the study, the patient-reported outcome (PRO) assessments was measured using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30; version 3) (Cull, 1998) at baseline, at the end

of cycles 1 to 6, and before surgery. The PRO data were scored, according to the EORTC scoring manual. A raw score was calculated as the average of items contributing to a scale and standardized to a range of 0 to 100 points. On global health status and functioning scales, a higher score indicated better status. Higher scores on symptom scales indicated worse symptoms.

### **Tumor-infiltrating lymphocytes (TILs)**

Tumor samples were collected when performing needle biopsy and surgery. The specimens were fixed in 10% formalin and paraffin-embedded. The tissue sections (3  $\mu$ m) were stained with hematoxylin and eosin (H&E) and the frequency of TILs were quantified manually by a pathologist in a blinded manner. The TILs scores were determined as the percentage of TILs in tumor area (tumor cells and stroma). The percentage of stromal TILs (sTILs) was calculated in accordance with the recommendations by an International TILs Working Group 2014 (Salgado et al., 2015).

### **Programmed cell death-ligand 1 (PD-L1) expression**

The expression of programmed cell death-ligand 1 (PD-L1) was characterized by immunohistochemistry (IHC) using anti-PD-L1 (clone SP142, Spring Bioscience, USA) and the percentages of PD-L1 positive tumor cells (TC) or infiltrating inflammatory cells (IC) were quantified.

209

## 210 **Statistical analysis**

211 All statistical analyses were conducted using SAS 9.4 (North Carolina, USA).  
 212 Continuous data are presented as mean and standard deviation (SD) or mean and 95%  
 213 confidence interval (CI). Categorical data are expressed as frequency and percentage.  
 214 The 95% CIs of pathological complete response rate, proportion of patients with  
 215 RCB-0 or RCB-I, and ORR were estimated using the Clopper-Pearson method.

216

## 217 **Results**

### 218 **Patient characteristics**

219 Between November 2021 and January 2022, 12 HR-positive, HER2-negative patients  
 220 were screened and recruited in the trial. Their baseline demographic and clinical  
 221 characteristics are shown in **Table 1**. They had a median age of 48.5 years (range, 36-  
 222 56) and the median tumor size of 33.5mm (range, 23-90) assessed by breast MRI.

223

### 224 **Patient outcomes**

225 After the completion of study treatment, 2 (16.7%, 95% CI 3.5%-46.0%) out of 12  
 226 patients achieved RCB 0–I tumor response, tpCR and PEPI 0 (**Table 2**). There were 3  
 227 (25.0%) patients reached bpCR. Overall, this study led to an ORR (as assessed by  
 228 breast MRI) of 91.7% (95% CI 62.5%-100%, **Fig. 1**). Rate of conversion from  
 229 mastectomy at baseline to breast conservation at surgery was 25.0% (95% CI 8.3%-

53.9%). The median Ki67 of surgical specimens for patients without pCR was 7% (range, 5-70).

### **Toxicity**

All patients completed the study treatment and AEs are summarized in **Table 3**. The most frequent grade 1-2 AEs were leukopenia (58.3%), hot flushes (50.0%) and lymphopenia (50.0%). There were some patients with Grade 3 AEs, including neutropenia (66.7%) and leukopenia (25.0%), but not grade 4 AEs. There was no serious AEs, no therapy-related death and no patients with dose interruption and reduction or treatment discontinuation in this population. Furthermore, there was no patient with radiation-related dermatitis and skin hyperpigmentation in this population.

### **Patient-reported outcome**

All patients completed the EORTC QLQ-C30 and had available results of PRO assessment (**Fig. 2**). There was no clinically significant deterioration in global health status, physical, role, emotional, cognitive and social functioning in this population.

### **Alteration in tumor immune microenvironment**

To examine the impact of this new neoadjuvant therapy on tumor environment, we performed H&E staining of tissue sections in 10 evaluable patients (**Fig. 3**). Compared with those in pre-treatment biopsied tissues, treatment significantly

increased the percentages of tumor-infiltrating lymphocytes (TILs) in the tumor environment (22.9% vs.10.7%,  $P=0.043$ ). IHC staining of PD-L1 revealed that there appeared no significant difference in the percent of PD-L1 positive immune cells and tumor cells between the pre-treatment and post-treatment specimens.

## Discussion

This pioneering study reported the efficacy and safety of sequential neoadjuvant radiotherapy and combination of dalpiciclib and exemestane in patients with HR-positive, HER2-negative breast cancer. This new therapeutic regimen achieved considerable anti-tumor activity with the RCB 0-I rate of 16.7% and ORR rate of 91.7%, respectively. More importantly, this combinatory therapeutic strategy was well tolerated in this population

CDK4/6 inhibitors have recently been preclinically identified as radiosensitizers, acting mainly through hindering DNA damage repair response after radiation exposure, and enhancing cell apoptosis and blocking cell cycle, which provide a conceptual basis of combining radiotherapy with a CDK4/6 inhibitor (Khasraw et al., 2017; Xie et al., 2019). Moreover, both radiotherapy and CDK4/6 inhibitors exert immunomodulatory effects and may synergize anticancer immune responses (Andrea M Pesch et al., 2020). SBRT with hypofractionation and higher radiation doses is more effective than conventional fractionation in triggering immune responses (Gandhi et al., 2015). Consistent with the basic research (Giulia Petroni et

272 al., 2021), we used the sequential treatment with SBRT and combination of  
273 dalpiciclib and exemestane.

274 Unlike HER2-positive and triple-negative breast cancer, NCT or NET for HR-positive,  
275 HER2-negative breast cancer only achieves a pCR rate of  $\leq 10\%$ (Cortazar et al.,  
276 2014) . Our study indicated that this novel therapeutic regiment achieved a pCR and  
277 RCB 0-I rate of 16.7% , while neoadjuvant therapies with combination of a CDK4/6  
278 inhibitor and letrozole led to a pCR rate of 0-3.8% and RCB 0-I rate of 6.1-7.7% and  
279 treatment with NCT resulted in a pCR rate of 5.8-5.9% and RCB 0-I rate of 11.8-15.7%  
280 in HR-positive, HER2-negative breast cancer patients(C. X. Ma et al., 2017; Prat et al.,  
281 2020). It is notable that pCR rate (commonly defined as ypT0/isN0) is not  
282 significantly associated with the prognosis of HR-positive, HER2-negative breast  
283 cancer(Cynthia X Ma et al., 2017). In addition, clinical trials to test different therapies  
284 for patients with HR-positive, HER2-negative breast cancer have focused on clinical  
285 response rates as important clinical endpoints. (Hurvitz et al., 2020; Johnston et al.,  
286 2019; Khan et al., 2020; Khasraw et al., 2017; C. X. Ma et al., 2017) In our study,  
287 treatment with the new therapeutic regiment led to eleven (91.7%) patients achieving  
288 objective responses by MRI, while previous studies have revealed that NET achieves  
289 an objective response rate of approximately 60% in HR-positive, HER2-negative  
290 breast cancer patients. (Sella et al., 2021) With the addition of SBRT, a slightly higher  
291 rate of patients changed from mastectomy to breast conservation compared with  
292 PALLET study (25.0% vs 14.1%). (Johnston et al., 2019) Therefore, our new

neoadjuvant therapeutic regiment appeared to improve the likelihood of pathological downstaging and achieve a margin-free resection, particularly for those with locally advanced and high-risk breast cancer.

Considering that treatment with radiotherapy or a CDK4/6 inhibitor can enhance anti-tumor immunity in vitro, We analyzed the impact of new neoadjuvant therapeutic regiment on alternation in biomarker expression in the numbers of TILs before and after the treatment., Our study showed a modest but statistically significant increase in the tumor tissues with the addition of SBRT. Apparently, sequential neoadjuvant therapies with radiotherapy, a CDK 4/6 inhibitor and exemestane turned non-responsive ‘cold’ tumors into responsive ‘hot’ ones. Therefore, our findings may provide significant insights into designing effective therapeutic strategies against HR-positive, HER2-negative breast cancer.

Patients with HR-positive, HER2-negative breast cancer were well-tolerated to the combinational regimen. During the observation period, those patients only developed grade 1-3 of AEs, including grade 3 neutropenia (66.7%), similar to that of combination of dalpiciclib and fulvestrant in the DAWNA-1 trial (84.2%). (Xu et al., 2021) There was no new AEs following therapies with radiotherapy and dalpiciclib in this population.

We recognized that our study had limitations, including a one-arm preliminary exploratory trial with small sample size. The small sample size limited the comparison of our data with historical data in the literature due to the potential bias. Thus, further

314 prospective randomized clinical trials with a larger population for longer treatment

315 duration are warranted to validate the findings.

316 In conclusion, our study provides novel insights into the neoadjuvant treatment of

317 HR+/HER2- breast cancer. The sequential radiotherapy and a CDK4/6 inhibitor plus

318 ET is feasible as neoadjuvant therapy for HR-positive, HER2 -negative breast cancers.

319 This neoadjuvant regimen was effective and well-tolerated, which could serve as a

320 promising alternative regimen in treatment of patients with HR-positive, HER2-

321 negative breast cancer. Further validation of these findings is warranted in a large-

322 scale study.

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

## 342 **Acknowledgments**

343 Jiangsu Hengrui Pharmaceuticals provided the study drug dalpiciclib free of charge  
344 for patients enrolled in the study. We thank the patients, their families involved in this  
345 study.

346

## 347 **Conflict of interest**

348 Jianfei Wang is the employee of Jiangsu Hengrui Pharmaceuticals Co., Ltd. Caigang  
349 Liu is a senior editor of eLife. Yongliang Yang is a reviewing editor of eLife. The  
350 other authors declare that no competing interests exist.

## 351 **Funding**

352 This research did not receive any specific grant from funding agencies in the public,  
353 commercial, or not-for-profit sectors.

354

355 **Author ORCIDs** : Caigang Liu <https://orcid.org/0000-0003-2083-235X>

356

## 357 **Data availability statement**

358 The raw clinical and imaging data are protected due to patient privacy laws. The  
359 datasets generated and/or analyzed during the current study are available from the  
360 corresponding author Caigang Liu on request for 10 years; de-identified clinical data  
361 and experimental data are available on request sharing, which will need the approval  
362 of the Institutional Ethical Committees. De-identified data will then be transferred to  
363 the inquiring investigator over secure file transfer.

364

## 365 **References**

- 366 Bosacki, C., Bouleftour, W., Sotton, S., Vallard, A., Daguene, E., Ouaz, H., Cojoracu, I.,  
367 Moslemi, D., Molekzadehmoghani, M., & Magné, N. (2021). CDK 4/6 inhibitors  
368 combined with radiotherapy: A review of literature. *Clin Transl Radiat Oncol*, 26, 79-  
369 85. <https://doi.org/10.1016/j.ctro.2020.11.010>
- 370
- 371 Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N.,  
372 Aguilar Lopez, B., Barrios, C. H., Bergh, J., Biganzoli, L., Boers-Doets, C. B.,  
373 Cardoso, M. J., Carey, L. A., Cortés, J., Curigliano, G., Diéras, V., El Saghir, N. S.,  
374 Eniu, A., . . . Winer, E. P. (2018). 4th ESO-ESMO International Consensus Guidelines  
375 for Advanced Breast Cancer (ABC 4)†. *Ann Oncol*, 29(8), 1634-1657.

376 <https://doi.org/10.1093/annonc/mdy192>

377

378 Chmura, S., Winter, K. A., Robinson, C., Pisansky, T. M., Borges, V., Al-Hallaq, H., Matuszak,

379 M., Park, S. S., Yi, S., Hasan, Y., Bazan, J., Wong, P., Yoon, H. A., Horton, J., Gan,

380 G., Milano, M. T., Sigurdson, E. R., Moughan, J., Salama, J. K., & White, J. (2021).

381 Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients

382 With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial. *JAMA Oncol*,

383 7(6), 845-852. <https://doi.org/10.1001/jamaoncol.2021.0687>

384

385 Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H.,

386 Cameron, D., Gianni, L., Valagussa, P., Swain, S. M., Prowell, T., Loibl, S.,

387 Wickerham, D. L., Bogaerts, J., Baselga, J., Perou, C., Blumenthal, G., Blohmer,

388 J., . . . von Minckwitz, G. (2014). Pathological complete response and long-term

389 clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet*, 384(9938),

390 164-172. [https://doi.org/10.1016/s0140-6736\(13\)62422-8](https://doi.org/10.1016/s0140-6736(13)62422-8)

391

392 Cox, J. A., & Swanson, T. A. (2013). Current modalities of accelerated partial breast

393 irradiation. *Nat Rev Clin Oncol*, 10(6), 344-356.

394 <https://doi.org/10.1038/nrclinonc.2013.65>

395

396 Cull, A. (1998). EORTC QLQ-30. A breach of copyright. *Int J Pancreatol*, 24(1), 64-65.

397 <https://doi.org/10.1007/bf02787535>

398

399 Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R.,

400 Pinter, T., Schmidt, M., Shparyk, Y., Thummala, A. R., Voytko, N. L., Fowst, C.,

401 Huang, X., Kim, S. T., Randolph, S., & Slamon, D. J. (2015). The cyclin-dependent

402 kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as

403 first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast

404 cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. *Lancet Oncol*, 16(1), 25-

405 35. [https://doi.org/10.1016/s1470-2045\(14\)71159-3](https://doi.org/10.1016/s1470-2045(14)71159-3)

406

407 Gandhi, S. J., Minn, A. J., Vonderheide, R. H., Wherry, E. J., Hahn, S. M., & Maity, A. (2015).

408 Awakening the immune system with radiation: optimal dose and fractionation. *Cancer*

409 *letters*, 368(2), 185-190. <https://doi.org/10.1016/j.canlet.2015.03.024>.

410

411 Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H.,

412 Trédan, O., Chen, S. C., Manso, L., Freedman, O. C., Garnica Jaliffe, G., Forrester,

413 T., Frenzel, M., Barriga, S., Smith, I. C., Bourayou, N., & Di Leo, A. (2017).

414 MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. *J Clin*

415 *Oncol*, 35(32), 3638-3646. <https://doi.org/10.1200/jco.2017.75.6155>

416

417 Gradishar, W. J., Moran, M. S., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Anderson, B.,  
 418 Burstein, H. J., Chew, H., Dang, C., Elias, A. D., Giordano, S. H., Goetz, M. P.,  
 419 Goldstein, L. J., Hurvitz, S. A., Isakoff, S. J., Jankowitz, R. C., Javid, S. H.,  
 420 Krishnamurthy, J., . . . Kumar, R. (2022). Breast Cancer, Version 3.2022, NCCN  
 421 Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*, 20(6), 691-722.  
 422 <https://doi.org/10.6004/jnccn.2022.0030>

423

424 Han, Y. K., Lee, J. H., Park, G. Y., Chun, S. H., Han, J. Y., Kim, S. D., Lee, J., Lee, C. W.,  
 425 Yang, K., & Lee, C. G. (2013). A possible usage of a CDK4 inhibitor for breast cancer  
 426 stem cell-targeted therapy. *Biochem Biophys Res Commun*, 430(4), 1329-1333.  
 427 <https://doi.org/10.1016/j.bbrc.2012.10.119>

428

429 Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S.,  
 430 Campone, M., Blackwell, K. L., André, F., Winer, E. P., Janni, W., Verma, S., Conte,  
 431 P., Arteaga, C. L., Cameron, D. A., Petrakova, K., Hart, L. L., Villanueva, C., Chan,  
 432 A., . . . O'Shaughnessy, J. (2016). Ribociclib as First-Line Therapy for HR-Positive,  
 433 Advanced Breast Cancer. *N Engl J Med*, 375(18), 1738-1748.  
 434 <https://doi.org/10.1056/NEJMoa1609709>

435

436 Hurvitz, S. A., Martin, M., Press, M. F., Chan, D., Fernandez-Abad, M., Petru, E., Rostorfer,  
437 R., Guarneri, V., Huang, C. S., Barriga, S., Wijayawardana, S., Brahmachary, M.,  
438 Ebert, P. J., Hossain, A., Liu, J., Abel, A., Aggarwal, A., Jansen, V. M., & Slamon, D.  
439 J. (2020). Potent Cell-Cycle Inhibition and Upregulation of Immune Response with  
440 Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in  
441 HR(+)/HER2(-) Breast Cancer. *Clin Cancer Res*, 26(3), 566-580.  
442 <https://doi.org/10.1158/1078-0432.CCR-19-1425>  
443  
444 Johnston, S., Puhalla, S., Wheatley, D., Ring, A., Barry, P., Holcombe, C., Boileau, J. F.,  
445 Provencher, L., Robidoux, A., Rimawi, M., McIntosh, S. A., Shalaby, I., Stein, R. C.,  
446 Thirlwell, M., Dolling, D., Morden, J., Snowdon, C., Perry, S., Cornman, C., . . .  
447 Jacobs, S. A. (2019). Randomized Phase II Study Evaluating Palbociclib in Addition  
448 to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast  
449 Cancer: PALLET Trial. *J Clin Oncol*, 37(3), 178-189.  
450 <https://doi.org/10.1200/jco.18.01624>  
451  
452 Khan, Q. J., O'Dea, A., Bardia, A., Kalinsky, K., Wisinski, K. B., O'Regan, R., Yuan, Y., Ma, C.  
453 X., Jahanzeb, M., Trivedi, M. S., Spring, L., Makhoul, I., Wagner, J. L., Winblad, O.,  
454 Amin, A. L., Blau, S., Crane, G. J., Elia, M., Hard, M., & Sharma, P. (2020). Letrozole  
455 + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer

456 (FELINE trial). *Journal of Clinical Oncology*, 38(15\_suppl), 505-505.

457 [https://doi.org/10.1200/JCO.2020.38.15\\_suppl.505](https://doi.org/10.1200/JCO.2020.38.15_suppl.505)

458

459 Khasraw, M., Chung, S., Day, B., Johns, T., Joshi, S., Madani, D., McDonald, K., & Whittaker,

460 S. (2017). Combination of palbociclib and radiotherapy for glioblastoma. *Cell Death*

461 *Discov* 2017;3:17033. <https://doi.org/10.1038/cddiscovery.2017.33>.

462

463 Ma, C. X., Gao, F., Luo, J., Northfelt, D. W., Goetz, M., Forero, A., Hoog, J., Naughton, M.,

464 Ademuyiwa, F., Suresh, R., Anderson, K. S., Margenthaler, J., Aft, R., Hobday, T.,

465 Moynihan, T., Gillanders, W., Cyr, A., Eberlein, T. J., Hieken, T., . . . Ellis, M. J.

466 (2017). NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor,

467 and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.

468 *Clin Cancer Res*, 23(15), 4055-4065. <https://doi.org/10.1158/1078-0432.Ccr-16-3206>

469

470 Parker, J. S., Mullins, M., Cheang, M. C., Leung, S., Voduc, D., Vickery, T., Davies, S.,

471 Fauron, C., He, X., Hu, Z., Quackenbush, J. F., Stijleman, I. J., Palazzo, J., Marron, J.

472 S., Nobel, A. B., Mardis, E., Nielsen, T. O., Ellis, M. J., Perou, C. M., & Bernard, P. S.

473 (2009). Supervised risk predictor of breast cancer based on intrinsic subtypes. *J Clin*

474 *Oncol*, 27(8), 1160-1167. <https://doi.org/10.1200/jco.2008.18.1370>

475

476 Pesch, A. M., Hirsh, N. H., Chandler, B. C., Michmerhuizen, A. R., Ritter, C. L., Androsiglio, M.  
 477 P., Wilder-Romans, K., Liu, M., Gersch, C. L., Larios, J. M., Pierce, L. J., Rae, J. M.,  
 478 & Speers, C. W. (2020). Short-term CDK4/6 Inhibition Radiosensitizes Estrogen  
 479 Receptor-Positive Breast Cancers. *Clin Cancer Res*, 26(24), 6568-6580.  
 480 <https://doi.org/10.1158/1078-0432.Ccr-20-2269>  
 481  
 482 Petroni, G., Buqué, A., Yamazaki, T., Bloy, N., Liberto, M. D., Chen-Kiang, S., Formenti, S. C.,  
 483 & Galluzzi, L. (2021). Radiotherapy Delivered before CDK4/6 Inhibitors Mediates  
 484 Superior Therapeutic Effects in ER(+) Breast Cancer. *Clin Cancer Res*, 27(7), 1855-  
 485 1863. <https://doi.org/10.1158/1078-0432.Ccr-20-3871>  
 486  
 487 Prat, A., Saura, C., Pascual, T., Hernando, C., Muñoz, M., Paré, L., Farré, B. G., Fernández,  
 488 P. L., Galván, P., & Chic, N. (2020). Ribociclib plus letrozole versus chemotherapy for  
 489 postmenopausal women with hormone receptor-positive, HER2-negative, luminal B  
 490 breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.  
 491 *The lancet oncology*, 21(1), 33-43. [https://doi: 10.1016/s1470-2045\(19\)30786-7](https://doi: 10.1016/s1470-2045(19)30786-7).  
 492  
 493 Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S.,  
 494 Van den Eynden, G., Baehner, F. L., Penault-Llorca, F., Perez, E. A., Thompson, E.  
 495 A., Symmans, W. F., Richardson, A. L., Brock, J., Criscitiello, C., Bailey, H., Ignatiadis,

496 M., Floris, G., . . . Loi, S. (2015). The evaluation of tumor-infiltrating lymphocytes  
497 (TILs) in breast cancer: recommendations by an International TILs Working Group  
498 2014. *Ann Oncol*, 26(2), 259-271. <https://doi.org/10.1093/annonc/mdu450>  
499  
500 Sella, T., Weiss, A., Mittendorf, E. A., King, T. A., Pilewskie, M., Giuliano, A. E., & Metzger-  
501 Filho, O. (2021). Neoadjuvant Endocrine Therapy in Clinical Practice: A Review.  
502 *JAMA Oncol*, 7(11), 1700-1708. <https://doi.org/10.1001/jamaoncol.2021.2132>  
503  
504 Xie, X., Zheng, W., Chen, T., Lin, W., Liao, Z., Liu, J., & Ding, Y. (2019). CDK4/6 inhibitor  
505 palbociclib amplifies the radiosensitivity to nasopharyngeal carcinoma cells via  
506 mediating apoptosis and suppressing DNA damage repair. *OncoTargets and therapy*,  
507 11107-11117. <https://doi: 10.2147/ott.S234221>.  
508  
509 Xu, B., Zhang, Q., Zhang, P., Hu, X., Li, W., Tong, Z., Sun, T., Teng, Y., Wu, X., Ouyang, Q.,  
510 Yan, X., Cheng, J., Liu, Q., Feng, J., Wang, X., Yin, Y., Shi, Y., Pan, Y., Wang, Y., . . .  
511 Zou, J. (2021). Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive  
512 and HER2-negative advanced breast cancer: a randomized, phase 3 trial. *Nat Med*,  
513 27(11), 1904-1909. <https://doi.org/10.1038/s41591-021-01562-9>  
514  
515

516 **Table 1: Baseline characteristics of the patients.**

|                                        | Patients (n=12) |
|----------------------------------------|-----------------|
| <b>Median age (range), years</b>       | 48.5 (36-56)    |
| ≤ 50                                   | 6 (50.0%)       |
| > 50                                   | 6 (50.0%)       |
| <b>Menopausal status</b>               |                 |
| Premenopausal                          | 6 (50.0%)       |
| Postmenopausal                         | 6 (50.0%)       |
| <b>Tumor size</b>                      |                 |
| T2                                     | 11 (91.7%)      |
| T3                                     | 1 (8.3%)        |
| <b>Lymph node status</b>               |                 |
| N0                                     | 5 (41.7%)       |
| N1                                     | 2 (16.7%)       |
| N2                                     | 5 (41.7%)       |
| <b>Clinical stage</b>                  |                 |
| IIA                                    | 4 (33.3%)       |
| IIB                                    | 3 (25.0%)       |
| IIIA                                   | 5 (41.7%)       |
| <b>Tumor grade</b>                     |                 |
| II                                     | 11 (91.7%)      |
| III                                    | 1 (8.3%)        |
| <b>ER expression</b>                   |                 |
| > 10%                                  | 12 (100.0%)     |
| <b>PgR expression</b>                  |                 |
| < 20%                                  | 3 (25.0%)       |
| ≥ 20%                                  | 9 (75.0%)       |
| <b>HER2 expression</b>                 |                 |
| Negative                               | 7 (58.3%)       |
| 1+                                     | 1 (8.3%)        |
| 2+, FISH                               | 4 (33.3%)       |
| <b>Median baseline Ki67 (range), %</b> | 35 (15-70)      |
| ≤ 14%                                  | 3 (25.0%)       |
| > 14%                                  | 9 (75.0%)       |

Data are n (%) or median (range).

ER: estrogen receptor; PgR: progesterone receptor; HER2: human epidermal growth

factor receptor 2; FISH: fluorescence in situ hybridization.

517 **Table 2: Pathological and clinical response (n=12).**

|                                                | n (%)      |
|------------------------------------------------|------------|
| <b>Total pathological complete response</b>    | 2 (16.7%)  |
| <b>Breast pathological complete response</b>   | 3 (25.0%)  |
| <b>Residual cancer burden score</b>            |            |
| 0                                              | 2 (16.7%)  |
| I                                              | 0          |
| II                                             | 6 (50.0%)  |
| III                                            | 4 (33.3%)  |
| <b>Radiological response</b>                   |            |
| Complete response                              | 2 (16.7%)  |
| Partial response                               | 9 (75.0%)  |
| Stable disease                                 | 1 (8.3%)   |
| Objective response rate                        | 11 (91.7%) |
| <b>Preoperative endocrine prognostic index</b> |            |
| 0                                              | 2 (16.7%)  |
| 1-3                                            | 0          |
| ≥4                                             | 10 (83.3%) |

Data are presented as n (%)

518

519

520

521 **Table 3: Treatment-emergent adverse events (n=12).**

|                                      | n (%)        |           |         |
|--------------------------------------|--------------|-----------|---------|
|                                      | Grade 1 or 2 | Grade 3   | Grade 4 |
| Neutropenia                          | 3 (25.0%)    | 8 (66.7%) | 0       |
| Leukopenia                           | 7 (58.3%)    | 3 (25.0%) | 0       |
| Hot flushes                          | 6 (50.0%)    | 0         | 0       |
| Lymphopenia                          | 6 (50.0%)    | 0         | 0       |
| Insomnia                             | 4 (33.3%)    | 0         | 0       |
| Alopecia                             | 4 (33.3%)    | 0         | 0       |
| Anemia                               | 4 (33.3%)    | 0         | 0       |
| Hyperuricemia                        | 4 (33.3%)    | 0         | 0       |
| Blood urea increased                 | 4 (33.3%)    | 0         | 0       |
| Rash                                 | 3 (25.0%)    | 0         | 0       |
| Thrombocytopenia                     | 3 (25.0%)    | 0         | 0       |
| Hyperglycemia                        | 3 (25.0%)    | 0         | 0       |
| Creatinine increased                 | 3 (25.0%)    | 0         | 0       |
| Fatigue                              | 3 (25.0%)    | 0         | 0       |
| Arthralgia                           | 2 (16.7%)    | 0         | 0       |
| γ-glutamyl transferase increased     | 2 (16.7%)    | 0         | 0       |
| Hypocalcemia                         | 2 (16.7%)    | 0         | 0       |
| Abnormal T wave of electrocardiogram | 2 (16.7%)    | 0         | 0       |
| Hyponatremia                         | 2 (16.7%)    | 0         | 0       |
| Lactate dehydrogenase increased      | 2 (16.7%)    | 0         | 0       |
| Diarrhea                             | 1 (8.3%)     | 0         | 0       |
| Headache                             | 1 (8.3%)     | 0         | 0       |
| Mucosal inflammation Constipation    | 1 (8.3%)     | 0         | 0       |
| Proteinuria                          | 1 (8.3%)     | 0         | 0       |
| Hypertriglyceridemia                 | 1 (8.3%)     | 0         | 0       |
| Alanine aminotransferase increased   | 1 (8.3%)     | 0         | 0       |

Data are presented as n (%).

522

523

## 524 **Figure legends**

525

526 **Figure 1:** Waterfall plot of best reduction in tumor measurement from baseline.

527 **Figure 2:** Mean change from baseline in QLQ-C30 over time. (A) Global health

528 status. (B-F) Physical, role, emotional, cognitive and social functioning.


529 **Figure 3:** TILs and PD-L1 changes before and after treatment. (A) Study schema. (B)

530 Representative TILs. Scale bar, 100  $\mu$ M. (C-E) Percentage of TILs, PD-L1 expression


531 in immune cell and tumor cell in paired specimens (n=10). Bars, boxes, and whiskers

532 represent median, interquartile range, and range, respectively.


533




a




b




c



d



e



f

